ProNAi Therapeutics Inc., a developer of drugs that target cancer by interfering with cancer cells’ DNA, announced that data from its ongoing Phase II clinical study of its drug candidate PNT2258 will be presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans Dec. 7-10.
Esperion Therapeutics Inc. Friday announced “positive” results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.
The biopharmaceutical company AlphaCore Pharma Friday announced it had started a Phase 1 study of its drug candidate, ACP-501, for the treatment of high-risk atherosclerosis and serious lipid metabolism disorders.
Ann Arbor-based Adeona Pharmaceuticals Inc. late Thursday reported top-line results from its clinical study evaluating reaZin for the dietary management of Alzheimer’s disease and mild cognitive impairment.
A Wayne State University obstetrician and gynecologist is conducting a clinical research study on alternative treatments — besides hysterectomy — for uterine fibroids. Jay Berman of the Wayne State University Physician Group is the only […]